Biotech Values

[DewDiligence]

TEVA MNTA: Michael McCaughan, author of the blog you posted, is off-base, IMO, to, call Teva’s position with respect to Lovenox and Copaxone a hedge. From the same blog:

So call it a hedge: if generic Lovenox is rejected, Teva’s Copaxone franchise is more secure.

This is a weak premise. The one thing Bill Marth said in the quotations cited by the blog that I would not characterize as BS is that Lovenox and Copaxone are very, very different compounds. I don’t think the FDA’s ruling on Lovenox will be strongly indicative of how the FDA will rule on Copaxone.